With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving ...

Researchers from the Broad Institute, Mass General, Stanford, and elsewhere are investigating why patients with South Asian ...

The firm, which plans to use the ticker symbol "MAZE" on the Nasdaq, develops drugs designed to mimic the protective effects ...

The firms will work together to create a bispecific antibody with two anti-cancer payloads and evaluate its therapeutic potential.

The firm is expanding its melanoma portfolio while launching new trials of T-cell receptor therapies in oncology, infectious disease, and autoimmune disease.

A new study found that fewer African and Asian patients had clinically actionable alterations for lung, breast, and colorectal cancer.

The firm will pause development of lunresertib and camonsertib while focusing on development of two newer programs.

These moves will enable the gene-editing company to focus resources on late-stage programs as it aims to launch a commercial product by 2027, it said.

Platforms using natural language processing are showing promise in scanning patients' records for biomarkers and other enrollment criteria for clinical trials.

The firm will use the funding to advance ongoing clinical trials of its autologous cell therapies for solid tumors.

The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.

NEW YORK – RheumaGen, a new company developing cell and gene therapies for autoimmune diseases, launched on Thursday with $15 million in Series A funding. The Series A funding round was led by SPRIM ...